Methods of reducing or hindering development of ischemia-reperfusion injury due to kidney transplantation with an antibody that inhibits granulocyte-colony stimulating factor (G-CSF) signaling

Patent metadata

Field	Value
Publication number	US-12264202-B2
Application number	US-202318152439-A
Country	US
Kind code	B2
Filing date	Jan 10, 2023
Priority date	Nov 29, 2017
Publication date	Apr 1, 2025
Grant date	Apr 1, 2025

Abstract

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

First claim

The invention claimed is:

1. A method for reducing or hindering development of ischemia-reperfusion injury in a subject, the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling, wherein the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation, wherein the tissue or organ transplantation is a kidney transplantation and wherein the compound that inhibits G-CSF signaling is an antibody that specifically binds to G-CSF receptor (G-CSFR) and neutralizes G-CSF signaling,
wherein the compound that inhibits G-CSF signaling is administered in an amount sufficient to have one or more of the following effects 24 hours after reperfusion:
(i) reduce or prevent an increase in serum or plasma creatinine levels;
(ii) reduce or prevent an increase in serum or plasma urea levels;
(iii) reduce or prevent neutrophil infiltration;
(iv) reduce or prevent macrophage infiltration;
(v) reduce or prevent complement C5 activation; and
(vi) reduce or prevent C5b-9 deposition.

2. The method of claim 1 , wherein the compound that inhibits G-CSF signaling is administered between 0 and 48 hours before ischemia or reperfusion.

3. The method of claim 2 , wherein the compound that inhibits G-CSF signaling is administered about 24 hours before ischemia or reperfusion.

4. The method of claim 2 , wherein the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or inhibit expression of one or more of the following 24 hours after reperfusion:
(i) kidney injury molecule 1 (KIM-1);
(ii) neutrophil gelatinase-associated lipocalin (NGAL);
(iii) interleukin 1 beta (IL-1β);
(iv) interleukin 6 (IL-6);
(v) tumor necrosis factor alpha (TNFα);
(vi) complement component 5a receptor 1 (C5AR1);
(vii) macrophage inflammatory protein 2-alpha (MIP2-alpha);
(viii) intercellular Adhesion Molecule 1 (ICAM-1);
(ix) E-selectin;
(x) C-X-C motif chemokine ligand 1 (CXCL1);
(xi) interleukin 8 receptor beta (IL-8Rβ); and
(xii) monocyte chemoattractant protein 1 (MCP-1).

5. The method of claim 1 , wherein the compound that inhibits G-CSF signaling is administered to the subject, wherein the subject is a tissue or organ transplantation recipient.

6. The method of claim 1 , wherein the compound that inhibits G-CSF signaling is administered to a tissue or organ transplantation donor prior to organ collection and/or to a tissue or organ prior to transplantation.

7. The method of claim 1 , wherein the compound that inhibits G-CSF signaling is administered to:
a) a tissue or organ transplant recipient prior to or at the time of transplanting the tissue or organ and then transplanting the tissue or organ into the tissue or organ transplant recipient;
b) a tissue or organ transplant donor prior to collection of the tissue or organ; collecting the tissue or organ and transplanting the tissue or organ into a tissue or organ transplant recipient; or
c) a harvested tissue or organ ex vivo and transplanting the harvested tissue or organ into a tissue or organ transplant recipient.

8. The method of claim 7 , wherein the compound is administered to the subject prior to or during transplantation and then one or more additional doses is administered to the recipient following transplantation.

9. The method of claim 1 , wherein the antibody comprises a VH comprising three complementarity determining regions (CDRs) of a VH comprising the amino acid sequence set forth in SEQ ID NO: 4 and a VL comprising three CDRs of a VL comprising the amino acid sequence set forth in SEQ ID NO: 5.

10. The method of claim 1 , wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 5.

11. The method of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 2 and a VL comprising the amino acid sequence set forth in SEQ ID NO: 3.

Assignees

• Csl Ltd

Inventors

• Vikstrom Ingela
• Baz Morelli Adriana
• Pearse Martin

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/505

  comprising antibodies · CPC title